Prevention of venous thrombosis after total hip arthroplasty. Antithrombin III and low-dose heparin compared with dextran 40.
The anticoagulant action of heparin is mediated through antithrombin III, and the postoperative decrease in the plasma concentration of antithrombin III may contribute to the relative ineffectiveness of prophylaxis with low-dose heparin in preventing venous thrombosis after total hip arthroplasty. We conducted a prospective, randomized trial to compare the effectiveness of a regimen of antithrombin III, given intravenously once daily, and low-dose heparin with a regimen of dextran 40, given intravenously, in preventing venographically documented venous thrombosis after total hip arthroplasty. The results demonstrated an incidence of venous thrombosis of 4.9 per cent in patients who received antithrombin III and heparin; this was significantly lower than the incidence (28.6 per cent) in patients who received dextran 40 (p less than 0.005). Venous thrombosis occurred only in patients who had total hip arthroplasty with a cemented prosthesis (fourteen of fifty-seven patients, or 24.6 per cent); none of the twenty-six patients in whom a non-cemented prosthesis was used had venous thrombosis (p less than 0.01). Of the patients in whom a cemented prosthesis had been inserted, the incidence of venous thrombosis was lower in those who were treated with antithrombin III and heparin (7.4 per cent) than in those who were treated with dextran 40 (40 per cent) (p less than 0.005). Postoperative levels of antithrombin III were maintained at more than 90 per cent of the baseline level in patients who received it; this was significantly higher than in patients who received dextran 40.(ABSTRACT TRUNCATED AT 250 WORDS)
Francis
C W
CW
University of Rochester School of Medicine and Dentistry, New York 14642.
Pellegrini
V D
VD
Marder
V J
VJ
Harris
C M
CM
Totterman
S
S
Gabriel
K R
KR
Baughman
D J
DJ
Roemer
S
S
Burke
J
J
Goodman
T L
TL
D000990:Antithrombin III / Q000008:administration & dosage* / Q000009:adverse effects / Q000032:analysis; D001843:Bone Cements / Q000627:therapeutic use; D003911:Dextrans / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006622:Hip Prosthesis; D006801:Humans; D010690:Phlebography; D011183:Postoperative Complications / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D011897:Random Allocation; D013924:Thrombophlebitis / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control*
D001843:Bone Cements; D003911:Dextrans; D000990:Antithrombin III; D006493:Heparin